1 hour ago
Eli Lilly (LLY) Stock Climbs on Breakthrough VERVE-102 Gene Therapy Results
Eli Lilly (LLY) stock climbs after VERVE-102 Heart-2 trial shows sustained LDL-C reduction up to 62% with strong safety data and Phase 2 plans confirmed.
The post Eli Lilly (LLY) Stock Climbs on Breakthrough VERVE-102 Gene Therapy Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 49 minutes ago
Security Matters (SMX) Stock Climbs as Verified Recycling Demand Intensifies
- 3 hours ago
Ralph Lauren (RL) Stock Soars 10% on Stellar China Sales and Q4 Earnings Beat
- 3 hours ago
SpaceX and OpenAI IPOs May Push Market Concentration Beyond Historic Levels in 2...
- 3 hours ago
Rigetti Computing (RGTI) Stock Soars 20% After Securing $100M Federal Quantum Co...
- 3 hours ago
Ericsson (ERIC) Stock Climbs on Strategic Headquarters Relocation to Hagastaden